APO Research
Talk to an analyst

APO RESEARCH · REPORT

Multivalent Influenza Vaccines

Compare research editions
View pricing & licenses

Selected research

Industry Research

Multivalent Influenza Vaccines Industry Research Report 2026

29 December 2025136 pages

Choose your research edition.

Industry ResearchMultivalent Influenza Vaccines Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Multivalent Influenza Vaccines Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Multivalent Influenza Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Multivalent Influenza Vaccines Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Multivalent Influenza Vaccines Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Multivalent Influenza Vaccines market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Multivalent Influenza Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Multivalent Influenza Vaccines is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Multivalent Influenza Vaccines is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Multivalent Influenza Vaccines include CSL, KM Biologics, Viatris, AstraZeneca, Bcht Biotechnology, Sinovac, Aleph Biomedical, GSK and ADIMMUNE Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Multivalent Influenza Vaccines market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Multivalent Influenza Vaccines Market by Company

CSL

KM Biologics

Viatris

AstraZeneca

Bcht Biotechnology

Sinovac

Aleph Biomedical

GSK

ADIMMUNE Corporation

Hualan Bio

Jiangsu GDK

Sanofi

Shanghai Institute of Biological Products

Wuhan Institute of Biological Products

Changchun Institute of Biological

Zhongyianke Biotech

Multivalent Influenza Vaccines Segment by Type

Quadrivalent Inactivated Influenza Vaccine (IIV4)

Trivalent Inactivated Influenza Vaccine (IIV3)

Trivalent Live Attenuated Vaccine (LAIV3)

Multivalent Influenza Vaccines Segment by Application

6 Months to 3 Years

Above 3 Years

Multivalent Influenza Vaccines Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multivalent Influenza Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Multivalent Influenza Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multivalent Influenza Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Multivalent Influenza Vaccines manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Multivalent Influenza Vaccines by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Multivalent Influenza Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Multivalent Influenza Vaccines Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Multivalent Influenza Vaccines Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Multivalent Influenza Vaccines Sales Market Share by Manufacturers (2021-2026) Table 8. Global Multivalent Influenza Vaccines Revenue of Manufacturers (2021-2026) Table 9. Global Multivalent Influenza Vaccines Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Multivalent Influenza Vaccines Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Multivalent Influenza Vaccines Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Multivalent Influenza Vaccines, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Multivalent Influenza Vaccines, Product Type & Application Table 14. Global Multivalent Influenza Vaccines Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Multivalent Influenza Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. CSL Company Information Table 19. CSL Business Overview Table 20. CSL Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. CSL Multivalent Influenza Vaccines Product Portfolio Table 22. CSL Recent Developments Table 23. KM Biologics Company Information Table 24. KM Biologics Business Overview Table 25. KM Biologics Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. KM Biologics Multivalent Influenza Vaccines Product Portfolio Table 27. KM Biologics Recent Developments Table 28. Viatris Company Information Table 29. Viatris Business Overview Table 30. Viatris Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Viatris Multivalent Influenza Vaccines Product Portfolio Table 32. Viatris Recent Developments Table 33. AstraZeneca Company Information Table 34. AstraZeneca Business Overview Table 35. AstraZeneca Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. AstraZeneca Multivalent Influenza Vaccines Product Portfolio Table 37. AstraZeneca Recent Developments Table 38. Bcht Biotechnology Company Information Table 39. Bcht Biotechnology Business Overview Table 40. Bcht Biotechnology Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Bcht Biotechnology Multivalent Influenza Vaccines Product Portfolio Table 42. Bcht Biotechnology Recent Developments Table 43. Sinovac Company Information Table 44. Sinovac Business Overview Table 45. Sinovac Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Sinovac Multivalent Influenza Vaccines Product Portfolio Table 47. Sinovac Recent Developments Table 48. Aleph Biomedical Company Information Table 49. Aleph Biomedical Business Overview Table 50. Aleph Biomedical Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Aleph Biomedical Multivalent Influenza Vaccines Product Portfolio Table 52. Aleph Biomedical Recent Developments Table 53. GSK Company Information Table 54. GSK Business Overview Table 55. GSK Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. GSK Multivalent Influenza Vaccines Product Portfolio Table 57. GSK Recent Developments Table 58. ADIMMUNE Corporation Company Information Table 59. ADIMMUNE Corporation Business Overview Table 60. ADIMMUNE Corporation Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. ADIMMUNE Corporation Multivalent Influenza Vaccines Product Portfolio Table 62. ADIMMUNE Corporation Recent Developments Table 63. Hualan Bio Company Information Table 64. Hualan Bio Business Overview Table 65. Hualan Bio Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Hualan Bio Multivalent Influenza Vaccines Product Portfolio Table 67. Hualan Bio Recent Developments Table 68. Jiangsu GDK Company Information Table 69. Jiangsu GDK Business Overview Table 70. Jiangsu GDK Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Jiangsu GDK Multivalent Influenza Vaccines Product Portfolio Table 72. Jiangsu GDK Recent Developments Table 73. Sanofi Company Information Table 74. Sanofi Business Overview Table 75. Sanofi Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Sanofi Multivalent Influenza Vaccines Product Portfolio Table 77. Sanofi Recent Developments Table 78. Shanghai Institute of Biological Products Company Information Table 79. Shanghai Institute of Biological Products Business Overview Table 80. Shanghai Institute of Biological Products Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Shanghai Institute of Biological Products Multivalent Influenza Vaccines Product Portfolio Table 82. Shanghai Institute of Biological Products Recent Developments Table 83. Wuhan Institute of Biological Products Company Information Table 84. Wuhan Institute of Biological Products Business Overview Table 85. Wuhan Institute of Biological Products Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Wuhan Institute of Biological Products Multivalent Influenza Vaccines Product Portfolio Table 87. Wuhan Institute of Biological Products Recent Developments Table 88. Changchun Institute of Biological Company Information Table 89. Changchun Institute of Biological Business Overview Table 90. Changchun Institute of Biological Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Changchun Institute of Biological Multivalent Influenza Vaccines Product Portfolio Table 92. Changchun Institute of Biological Recent Developments Table 93. Zhongyianke Biotech Company Information Table 94. Zhongyianke Biotech Business Overview Table 95. Zhongyianke Biotech Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Zhongyianke Biotech Multivalent Influenza Vaccines Product Portfolio Table 97. Zhongyianke Biotech Recent Developments Table 98. Global Multivalent Influenza Vaccines Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 99. Global Multivalent Influenza Vaccines Sales by Region (2021-2026) & (K Units) Table 100. Global Multivalent Influenza Vaccines Sales Market Share by Region (2021-2026) Table 101. Global Multivalent Influenza Vaccines Sales by Region (2027-2032) & (K Units) Table 102. Global Multivalent Influenza Vaccines Sales Market Share by Region (2027-2032) Table 103. Global Multivalent Influenza Vaccines Revenue by Region (2021-2026) & (US$ Million) Table 104. Global Multivalent Influenza Vaccines Revenue Market Share by Region (2021-2026) Table 105. Global Multivalent Influenza Vaccines Revenue by Region (2027-2032) & (US$ Million) Table 106. Global Multivalent Influenza Vaccines Revenue Market Share by Region (2027-2032) Table 107. North America Multivalent Influenza Vaccines Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. North America Multivalent Influenza Vaccines Sales by Country (2021-2026) & (K Units) Table 109. North America Multivalent Influenza Vaccines Sales by Country (2027-2032) & (K Units) Table 110. North America Multivalent Influenza Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 111. North America Multivalent Influenza Vaccines Revenue by Country (2027-2032) & (US$ Million) Table 112. Europe Multivalent Influenza Vaccines Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Europe Multivalent Influenza Vaccines Sales by Country (2021-2026) & (K Units) Table 114. Europe Multivalent Influenza Vaccines Sales by Country (2027-2032) & (K Units) Table 115. Europe Multivalent Influenza Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 116. Europe Multivalent Influenza Vaccines Revenue by Country (2027-2032) & (US$ Million) Table 117. Asia Pacific Multivalent Influenza Vaccines Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Asia Pacific Multivalent Influenza Vaccines Sales by Country (2021-2026) & (K Units) Table 119. Asia Pacific Multivalent Influenza Vaccines Sales by Country (2027-2032) & (K Units) Table 120. Asia Pacific Multivalent Influenza Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 121. Asia Pacific Multivalent Influenza Vaccines Revenue by Country (2027-2032) & (US$ Million) Table 122. South America Multivalent Influenza Vaccines Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. South America Multivalent Influenza Vaccines Sales by Country (2021-2026) & (K Units) Table 124. South America Multivalent Influenza Vaccines Sales by Country (2027-2032) & (K Units) Table 125. South America Multivalent Influenza Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 126. South America Multivalent Influenza Vaccines Revenue by Country (2027-2032) & (US$ Million) Table 127. Middle East and Africa Multivalent Influenza Vaccines Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Middle East and Africa Multivalent Influenza Vaccines Sales by Country (2021-2026) & (K Units) Table 129. Middle East and Africa Multivalent Influenza Vaccines Sales by Country (2027-2032) & (K Units) Table 130. Middle East and Africa Multivalent Influenza Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 131. Middle East and Africa Multivalent Influenza Vaccines Revenue by Country (2027-2032) & (US$ Million) Table 132. Global Multivalent Influenza Vaccines Sales by Type (2021-2026) & (K Units) Table 133. Global Multivalent Influenza Vaccines Sales by Type (2027-2032) & (K Units) Table 134. Global Multivalent Influenza Vaccines Sales Market Share by Type (2021-2026) Table 135. Global Multivalent Influenza Vaccines Sales Market Share by Type (2027-2032) Table 136. Global Multivalent Influenza Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 137. Global Multivalent Influenza Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 138. Global Multivalent Influenza Vaccines Revenue Market Share by Type (2021-2026) Table 139. Global Multivalent Influenza Vaccines Revenue Market Share by Type (2027-2032) Table 140. Global Multivalent Influenza Vaccines Price by Type (2021-2026) & (US$/Unit) Table 141. Global Multivalent Influenza Vaccines Price by Type (2027-2032) & (US$/Unit) Table 142. Global Multivalent Influenza Vaccines Sales by Application (2021-2026) & (K Units) Table 143. Global Multivalent Influenza Vaccines Sales by Application (2027-2032) & (K Units) Table 144. Global Multivalent Influenza Vaccines Sales Market Share by Application (2021-2026) Table 145. Global Multivalent Influenza Vaccines Sales Market Share by Application (2027-2032) Table 146. Global Multivalent Influenza Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 147. Global Multivalent Influenza Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 148. Global Multivalent Influenza Vaccines Revenue Market Share by Application (2021-2026) Table 149. Global Multivalent Influenza Vaccines Revenue Market Share by Application (2027-2032) Table 150. Global Multivalent Influenza Vaccines Price by Application (2021-2026) & (US$/Unit) Table 151. Global Multivalent Influenza Vaccines Price by Application (2027-2032) & (US$/Unit) Table 152. Key Raw Materials Table 153. Raw Materials Key Suppliers Table 154. Multivalent Influenza Vaccines Distributors List Table 155. Multivalent Influenza Vaccines Customers List Table 156. Multivalent Influenza Vaccines Industry Trends Table 157. Multivalent Influenza Vaccines Industry Drivers Table 158. Multivalent Influenza Vaccines Industry Restraints Table 159. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Multivalent Influenza Vaccines Product Image Figure 5. Global Multivalent Influenza Vaccines Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Multivalent Influenza Vaccines Market Size (2021-2032) & (US$ Million) Figure 7. Global Multivalent Influenza Vaccines Sales (2021-2032) & (K Units) Figure 8. Global Multivalent Influenza Vaccines Average Price (US$/Unit) & (2021-2032) Figure 9. Quadrivalent Inactivated Influenza Vaccine (IIV4) Product Image Figure 10. Trivalent Inactivated Influenza Vaccine (IIV3) Product Image Figure 11. Trivalent Live Attenuated Vaccine (LAIV3) Product Image Figure 12. 6 Months to 3 Years Product Image Figure 13. Above 3 Years Product Image Figure 14. Global Multivalent Influenza Vaccines Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Multivalent Influenza Vaccines, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Multivalent Influenza Vaccines Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Multivalent Influenza Vaccines Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Multivalent Influenza Vaccines Sales by Region in 2025 Figure 20. Global Multivalent Influenza Vaccines Revenue by Region in 2025 Figure 21. North America Multivalent Influenza Vaccines Market Size by Country in 2025 Figure 22. North America Multivalent Influenza Vaccines Sales Market Share by Country (2021-2032) Figure 23. North America Multivalent Influenza Vaccines Revenue Market Share by Country (2021-2032) Figure 24. United States Multivalent Influenza Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Multivalent Influenza Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Europe Multivalent Influenza Vaccines Market Size by Country in 2025 Figure 27. Europe Multivalent Influenza Vaccines Sales Market Share by Country (2021-2032) Figure 28. Europe Multivalent Influenza Vaccines Revenue Market Share by Country (2021-2032) Figure 29. Germany Multivalent Influenza Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. France Multivalent Influenza Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. U.K. Multivalent Influenza Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Italy Multivalent Influenza Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Netherlands Multivalent Influenza Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Asia Pacific Multivalent Influenza Vaccines Market Size by Country in 2025 Figure 35. Asia Pacific Multivalent Influenza Vaccines Sales Market Share by Country (2021-2032) Figure 36. Asia Pacific Multivalent Influenza Vaccines Revenue Market Share by Country (2021-2032) Figure 37. China Multivalent Influenza Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Japan Multivalent Influenza Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. South Korea Multivalent Influenza Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. India Multivalent Influenza Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Australia Multivalent Influenza Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. China Taiwan Multivalent Influenza Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Southeast Asia Multivalent Influenza Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Southeast Asia Multivalent Influenza Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South America Multivalent Influenza Vaccines Market Size by Country in 2025 Figure 46. South America Multivalent Influenza Vaccines Sales Market Share by Country (2021-2032) Figure 47. South America Multivalent Influenza Vaccines Revenue Market Share by Country (2021-2032) Figure 48. Mexico Multivalent Influenza Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Brazil Multivalent Influenza Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Argentina Multivalent Influenza Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Middle East and Africa Multivalent Influenza Vaccines Market Size by Country in 2025 Figure 52. Middle East and Africa Multivalent Influenza Vaccines Sales Market Share by Country (2021-2032) Figure 53. Middle East and Africa Multivalent Influenza Vaccines Revenue Market Share by Country (2021-2032) Figure 54. Turkey Multivalent Influenza Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Saudi Arabia Multivalent Influenza Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. UAE Multivalent Influenza Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Global Multivalent Influenza Vaccines Sales Market Share by Type (2021-2032) Figure 58. Global Multivalent Influenza Vaccines Revenue Market Share by Type (2021-2032) Figure 59. Global Multivalent Influenza Vaccines Price (US$/Unit) by Type (2021-2032) Figure 60. Global Multivalent Influenza Vaccines Sales Market Share by Application (2021-2032) Figure 61. Global Multivalent Influenza Vaccines Revenue Market Share by Application (2021-2032) Figure 62. Global Multivalent Influenza Vaccines Price (US$/Unit) by Application (2021-2032) Figure 63. Multivalent Influenza Vaccines Value Chain Figure 64. Multivalent Influenza Vaccines Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Multivalent Influenza Vaccines Industry Opportunities and Challenges

Scope & coverage.

Types
  • Quadrivalent Inactivated Influenza Vaccine (IIV4)
  • Trivalent Inactivated Influenza Vaccine (IIV3)
  • Trivalent Live Attenuated Vaccine (LAIV3)
Applications
  • 6 Months to 3 Years
  • Above 3 Years
Companies covered
  • CSL
  • KM Biologics
  • Viatris
  • AstraZeneca
  • Bcht Biotechnology
  • Sinovac
  • Aleph Biomedical
  • GSK
  • ADIMMUNE Corporation
  • Hualan Bio
  • Jiangsu GDK
  • Sanofi
  • Shanghai Institute of Biological Products
  • Wuhan Institute of Biological Products
  • Changchun Institute of Biological
  • Zhongyianke Biotech

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Multivalent Influenza Vaccines Market Size (2021-2032)
  4. 2.2.2 Global Multivalent Influenza Vaccines Sales (2021-2032)
  5. 2.2.3 Global Multivalent Influenza Vaccines Market Average Price (2021-2032)
  6. 2.3 Multivalent Influenza Vaccines by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Quadrivalent Inactivated Influenza Vaccine (IIV4)
  9. 2.3.3 Trivalent Inactivated Influenza Vaccine (IIV3)
  10. 2.3.4 Trivalent Live Attenuated Vaccine (LAIV3)
  11. 2.4 Multivalent Influenza Vaccines by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 6 Months to 3 Years
  14. 2.4.3 Above 3 Years
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Multivalent Influenza Vaccines Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Multivalent Influenza Vaccines Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Multivalent Influenza Vaccines Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Multivalent Influenza Vaccines Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Multivalent Influenza Vaccines Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Multivalent Influenza Vaccines, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Multivalent Influenza Vaccines, Product Type & Application
  8. 3.8 Global Manufacturers of Multivalent Influenza Vaccines, Established Date
  9. 3.9 Global Multivalent Influenza Vaccines Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 CSL
  2. 4.1.1 CSL Company Information
  3. 4.1.2 CSL Business Overview
  4. 4.1.3 CSL Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 CSL Multivalent Influenza Vaccines Product Portfolio
  6. 4.1.5 CSL Recent Developments
  7. 4.2 KM Biologics
  8. 4.2.1 KM Biologics Company Information
  9. 4.2.2 KM Biologics Business Overview
  10. 4.2.3 KM Biologics Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 KM Biologics Multivalent Influenza Vaccines Product Portfolio
  12. 4.2.5 KM Biologics Recent Developments
  13. 4.3 Viatris
  14. 4.3.1 Viatris Company Information
  15. 4.3.2 Viatris Business Overview
  16. 4.3.3 Viatris Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Viatris Multivalent Influenza Vaccines Product Portfolio
  18. 4.3.5 Viatris Recent Developments
  19. 4.4 AstraZeneca
  20. 4.4.1 AstraZeneca Company Information
  21. 4.4.2 AstraZeneca Business Overview
  22. 4.4.3 AstraZeneca Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 AstraZeneca Multivalent Influenza Vaccines Product Portfolio
  24. 4.4.5 AstraZeneca Recent Developments
  25. 4.5 Bcht Biotechnology
  26. 4.5.1 Bcht Biotechnology Company Information
  27. 4.5.2 Bcht Biotechnology Business Overview
  28. 4.5.3 Bcht Biotechnology Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Bcht Biotechnology Multivalent Influenza Vaccines Product Portfolio
  30. 4.5.5 Bcht Biotechnology Recent Developments
  31. 4.6 Sinovac
  32. 4.6.1 Sinovac Company Information
  33. 4.6.2 Sinovac Business Overview
  34. 4.6.3 Sinovac Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Sinovac Multivalent Influenza Vaccines Product Portfolio
  36. 4.6.5 Sinovac Recent Developments
  37. 4.7 Aleph Biomedical
  38. 4.7.1 Aleph Biomedical Company Information
  39. 4.7.2 Aleph Biomedical Business Overview
  40. 4.7.3 Aleph Biomedical Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Aleph Biomedical Multivalent Influenza Vaccines Product Portfolio
  42. 4.7.5 Aleph Biomedical Recent Developments
  43. 4.8 GSK
  44. 4.8.1 GSK Company Information
  45. 4.8.2 GSK Business Overview
  46. 4.8.3 GSK Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 GSK Multivalent Influenza Vaccines Product Portfolio
  48. 4.8.5 GSK Recent Developments
  49. 4.9 ADIMMUNE Corporation
  50. 4.9.1 ADIMMUNE Corporation Company Information
  51. 4.9.2 ADIMMUNE Corporation Business Overview
  52. 4.9.3 ADIMMUNE Corporation Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 ADIMMUNE Corporation Multivalent Influenza Vaccines Product Portfolio
  54. 4.9.5 ADIMMUNE Corporation Recent Developments
  55. 4.10 Hualan Bio
  56. 4.10.1 Hualan Bio Company Information
  57. 4.10.2 Hualan Bio Business Overview
  58. 4.10.3 Hualan Bio Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Hualan Bio Multivalent Influenza Vaccines Product Portfolio
  60. 4.10.5 Hualan Bio Recent Developments
  61. 4.11 Jiangsu GDK
  62. 4.11.1 Jiangsu GDK Company Information
  63. 4.11.2 Jiangsu GDK Business Overview
  64. 4.11.3 Jiangsu GDK Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Jiangsu GDK Multivalent Influenza Vaccines Product Portfolio
  66. 4.11.5 Jiangsu GDK Recent Developments
  67. 4.12 Sanofi
  68. 4.12.1 Sanofi Company Information
  69. 4.12.2 Sanofi Business Overview
  70. 4.12.3 Sanofi Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Sanofi Multivalent Influenza Vaccines Product Portfolio
  72. 4.12.5 Sanofi Recent Developments
  73. 4.13 Shanghai Institute of Biological Products
  74. 4.13.1 Shanghai Institute of Biological Products Company Information
  75. 4.13.2 Shanghai Institute of Biological Products Business Overview
  76. 4.13.3 Shanghai Institute of Biological Products Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Shanghai Institute of Biological Products Multivalent Influenza Vaccines Product Portfolio
  78. 4.13.5 Shanghai Institute of Biological Products Recent Developments
  79. 4.14 Wuhan Institute of Biological Products
  80. 4.14.1 Wuhan Institute of Biological Products Company Information
  81. 4.14.2 Wuhan Institute of Biological Products Business Overview
  82. 4.14.3 Wuhan Institute of Biological Products Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Wuhan Institute of Biological Products Multivalent Influenza Vaccines Product Portfolio
  84. 4.14.5 Wuhan Institute of Biological Products Recent Developments
  85. 4.15 Changchun Institute of Biological
  86. 4.15.1 Changchun Institute of Biological Company Information
  87. 4.15.2 Changchun Institute of Biological Business Overview
  88. 4.15.3 Changchun Institute of Biological Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Changchun Institute of Biological Multivalent Influenza Vaccines Product Portfolio
  90. 4.15.5 Changchun Institute of Biological Recent Developments
  91. 4.16 Zhongyianke Biotech
  92. 4.16.1 Zhongyianke Biotech Company Information
  93. 4.16.2 Zhongyianke Biotech Business Overview
  94. 4.16.3 Zhongyianke Biotech Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Zhongyianke Biotech Multivalent Influenza Vaccines Product Portfolio
  96. 4.16.5 Zhongyianke Biotech Recent Developments
5 Global Multivalent Influenza Vaccines Market Scenario by Region
  1. 5.1 Global Multivalent Influenza Vaccines Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Multivalent Influenza Vaccines Sales by Region: 2021-2032
  3. 5.2.1 Global Multivalent Influenza Vaccines Sales by Region: 2021-2026
  4. 5.2.2 Global Multivalent Influenza Vaccines Sales by Region: 2027-2032
  5. 5.3 Global Multivalent Influenza Vaccines Revenue by Region: 2021-2032
  6. 5.3.1 Global Multivalent Influenza Vaccines Revenue by Region: 2021-2026
  7. 5.3.2 Global Multivalent Influenza Vaccines Revenue by Region: 2027-2032
  8. 5.4 North America Multivalent Influenza Vaccines Market Facts & Figures by Country
  9. 5.4.1 North America Multivalent Influenza Vaccines Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Multivalent Influenza Vaccines Sales by Country (2021-2032)
  11. 5.4.3 North America Multivalent Influenza Vaccines Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Multivalent Influenza Vaccines Market Facts & Figures by Country
  15. 5.5.1 Europe Multivalent Influenza Vaccines Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Multivalent Influenza Vaccines Sales by Country (2021-2032)
  17. 5.5.3 Europe Multivalent Influenza Vaccines Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Multivalent Influenza Vaccines Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Multivalent Influenza Vaccines Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Multivalent Influenza Vaccines Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Multivalent Influenza Vaccines Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Multivalent Influenza Vaccines Market Facts & Figures by Country
  35. 5.7.1 South America Multivalent Influenza Vaccines Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Multivalent Influenza Vaccines Sales by Country (2021-2032)
  37. 5.7.3 South America Multivalent Influenza Vaccines Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Multivalent Influenza Vaccines Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Multivalent Influenza Vaccines Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Multivalent Influenza Vaccines Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Multivalent Influenza Vaccines Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Multivalent Influenza Vaccines Sales by Type (2021-2032)
  2. 6.1.1 Global Multivalent Influenza Vaccines Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Multivalent Influenza Vaccines Sales Market Share by Type (2021-2032)
  4. 6.2 Global Multivalent Influenza Vaccines Revenue by Type (2021-2032)
  5. 6.2.1 Global Multivalent Influenza Vaccines Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Multivalent Influenza Vaccines Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Multivalent Influenza Vaccines Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Multivalent Influenza Vaccines Sales by Application (2021-2032)
  2. 7.1.1 Global Multivalent Influenza Vaccines Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Multivalent Influenza Vaccines Sales Market Share by Application (2021-2032)
  4. 7.2 Global Multivalent Influenza Vaccines Revenue by Application (2021-2032)
  5. 7.2.1 Global Multivalent Influenza Vaccines Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Multivalent Influenza Vaccines Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Multivalent Influenza Vaccines Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Multivalent Influenza Vaccines Value Chain Analysis
  2. 8.1.1 Multivalent Influenza Vaccines Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Multivalent Influenza Vaccines Production Mode & Process
  5. 8.2 Multivalent Influenza Vaccines Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Multivalent Influenza Vaccines Distributors
  8. 8.2.3 Multivalent Influenza Vaccines Customers
9 Global Multivalent Influenza Vaccines Analyzing Market Dynamics
  1. 9.1 Multivalent Influenza Vaccines Industry Trends
  2. 9.2 Multivalent Influenza Vaccines Industry Drivers
  3. 9.3 Multivalent Influenza Vaccines Industry Opportunities and Challenges
  4. 9.4 Multivalent Influenza Vaccines Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst